162 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
not to remove from the Company’s premises any property of the PLC or any Group Company including, but not limited to, documents, records, or materials … Executive discovers this is incorrect, Executive shall promptly return any such materials to Executive’s former employer. The Company does not want
8-K
EX-10.2
c2prml2 wk
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
p70 iregg4vfgamd3
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
ldddi0z
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
hk2jgtoipx
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
34yeoaw4y12k88n
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
pb956q36p 1lr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
zaf4 ekuvz
30 May 23
Business combination disclosure
4:21pm
8-K
ld4q44l l8
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
qtuaw
22 May 23
Business combination disclosure
7:01am
8-K
8hz91z 9niiozatfsc6y
22 May 23
Other Events
6:59am
8-K
EX-99.1
xpm4bc40smm ox
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
bqe 5eq2cy
20 Apr 23
Prospectus supplement
4:32pm